THE latest data on the use of Boehringer Ingelheim's Jardiance (empagliflozin) presented at this year's meeting of the European Association for the Study of Diabetes (EASD) demonstrated lower risk of cardiovascular death compared with placebo regardless of background metformin or sulphonylurea use.
CLICK HERE to read the research.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Sep 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Sep 17
